BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2012

View Archived Issues

FX-006 achieves prolonged therapeutic concentrations in osteoarthritis

Read More

ViiV Healthcare files for approval of dolutegravir

Read More

Bioengineering of a human lung-on-a-chip model for drug efficacy and toxicity screening

Read More

ALKS-5461 as a novel combination therapy for the treatment of cocaine abuse

Read More

Scientists at the Wistar Institute prepare new vaccines for influenza A

Read More

MacroGenics discloses novel diabodies for the treatment of cancer

Read More

University of Georgia patents new antiviral prodrugs

Read More

Array BioPharma prepares new Trk-A inhibitors

Read More

Merck & Co. synthesizes novel M1 receptor positive allosteric modulators

Read More

Genentech presents two antibody-drug conjugates for the treatment of NHL

Read More

Mechanisms for improving blood cell count following hematopoietic progenitor cell transplant

Read More

Researchers at institutes in California present new protein kinase inhibitors

Read More

Preclinical studies validate Immuron's Clostridium therapeutic

Read More

EyeGate Pharma enrolls last patient in phase III EGP-437 trial

Read More

La Jolla Pharmaceutical reports promising results from preclinical GCS-100 study

Read More

Acasti Pharma updates on CaPre development

Read More

In vitro A-1014907 data show promise in multiple myeloma

Read More

Lorus Therapeutics and Brock University to develop novel anticancer drugs

Read More

GlaxoSmithKline and Theravance submit NDA for umeclidinium bromide/vilanterol

Read More

Navidea Biopharmaceuticals submits MAA for Lymphoseek to the EMA

Read More

Vanda Pharmaceuticals reports phase III data for the circadian regulator tasimelteon

Read More

Actelion's ponesimod trial meets primary endpoint in psoriasis

Read More

Tranzyme Pharma stops DIGEST trial of TZP-102 due to insufficient efficacy

Read More

Interim safety results reported from phase IIa study of stem cell therapy in RA

Read More

Co-development agreement reached for NTCell for Parkinson's disease

Read More

Shire obtains approval for Elvanse in ADHD under European decentralized procedure

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing